I’m out. Sold at $2.62.
It seems MSB will need a confirmatory trial (subject to the FDA agreeing to it). Mixed results buried in a difficult to read announcement. MSB have again put themselves in a weak bargaining position due to trials design. Potential partners know this.
The FDA’s decision to reject the ODAC finding last year shows just how high the bar is for an FDA approval. Management should conduct a review of their pipelines and only focus on those with the highest probability of achieving regulatory approval with the FDA. Put the others on the back-burner and get some approval runs on the board first, otherwise they will just keep burning cash at an extraordinary rate.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-343
-
- There are more pages in this discussion • 761 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |